摘要
根据酵母和人类在固醇代谢机制方面的高度保守性,通过构建不同的麦角固醇合成相关基因缺失菌株建立了一种新的基于酵母菌的降胆固醇药物筛选模型,并以作用机理明确的药物洛伐他汀和吉非罗其作为对照标准,探索了本模型对降胆固醇药物的筛选条件.进而利用本模型对临床报道有降胆固醇作用的传统中药:丹参、山楂以及成分明确、疗效显著的复方亚油酸胶囊和月见草油胶丸进行了筛选试验.结果验证了利用本模型筛选药物的可行性,并初步分析了上述药物可能的作用机理.
Both Saccharonlyces cerevisiae and Homo sapiens are same in most part of sterol biosynthesis pathway except Desmosterol become ergosterol in S. cerevisiae and the counterpart in human is cholesterol. Using the gene-disrupted S.cerevisiae strains, we combined different deletions by yeast sporulation, mating and tetrad dissection, and the growth status of the deletion strains growing in drug-containing medium were tested using mevinolin and gemfibrozil as the positive control drugs. Compound ethyl linoleate, Oenothera biennis oil and .some Chinese traditional medicine such as haw and Salvia miltiorrhiza Bunge were tested by this drug screen model. The results of the work were analyzed and discussed.
出处
《复旦学报（自然科学版）》
CAS
CSCD
北大核心
2005年第4期490-497,共8页
Journal of Fudan University：Natural Science
基金
上海市经委高新技术产业科技开发资助项目
上海市科委重点科技资助项目(02ZD19146)
关键词
酵母
胆固醇
药物筛选
saccharomyces cerevisiae
cholesterol
drug screening
